Company Encyclopedia
View More
name
Protara Therapeutic
TARA.US
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
1.946 T
TARA.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Protara prices public offering at $5.75/share, offering 13,043,479 shares for approx $75 million. The amount period is for non-recording fees and discounts

    Protara Therapeutics, Inc. announced a public offering of 13,043,479 shares of common stock at a price of $5.75 per share, totaling approximately $75 million. The underwriters have the option to purchase an additional 1,956,521 shares. This offering is expected to be completed on December 8, 2025, and the proceeds will be used for the clinical development of TARA-002 and other projects, with a portion of the funds potentially allocated for working capital and general corporate purposes

    Unusual Whales·
    US
    TARA
    +1.03%
    Unusual Whales·
    US
    TARA
    +1.03%

    BUZZ-Biotech firm Protara tumbles on planned $75 mln equity raise

    Protara Therapeutics plans a $75 million equity raise, causing shares to drop 12% to $6.05. The funds will support the development of TARA-002 for bladder cancer and lymphatic malformations. With a market cap of $265 million, the offering is managed by JP Morgan, TD Cowen, and Piper Sandler. Despite the drop, TARA shares have gained 58% QTD and 30% YTD, with analysts bullish and a median price target of $25.

    Reuters·
    US
    TARA
    +1.03%
    Reuters·
    US
    TARA
    +1.03%

    Protara Announces Pricing of $75 Million Public Offering | TARA Stock News

    Protara Therapeutics announced a $75 million public offering of 13,043,479 shares at $5.75 per share. The offering includes a 30-day option for underwriters to purchase an additional 1,956,521 shares. Proceeds will fund clinical development of TARA-002 and other programs, with J.P. Morgan, TD Cowen, and Piper Sandler as joint managers. The offering closes on December 8, 2025.

    StockTitan·
    US
    TARA
    +1.03%
    StockTitan·
    US
    TARA
    +1.03%

    HC Wainwright Has Positive Outlook for TARA Q4 Earnings

    HC Wainwright has increased its Q4 2025 EPS estimates for Protara Therapeutics, now expecting ($0.32) per share, up from ($0.36). The firm maintains a "Buy" rating with a $23.00 price target. Protara's stock opened at $7.56, with a market cap of $291.72 million. Analysts have a "Moderate Buy" rating, but Weiss Ratings issued a "sell" rating. Institutional investors own 38.13% of the stock. Protara is advancing therapies for cancer and rare diseases, with its lead program TARA-002 in Phase II trials.

    Market Beat·
    US
    TARA
    +1.03%
    Market Beat·
    US
    TARA
    +1.03%

    Protara Therapeutics (TARA) Receives a Buy from TD Cowen

    TD Cowen analyst Stacy Ku maintained a Buy rating on Protara Therapeutics, setting a price target of $30.00, while the stock closed at $6.71. The consensus among analysts is a Strong Buy with a $25.00 average price target, indicating a 272.58% upside. Oppenheimer also reiterated a Buy rating with a $25.00 target.

    Tip Ranks·
    US
    TARA
    +1.03%
    Tip Ranks·
    US
    TARA
    +1.03%
    © 2025 Longbridge｜Disclaimer